Cusatuzumab Usage And Synthesis

Description

Cusatuzumab is designed as a first-in-class, high-affinity anti-CD70 monoclonal antibody with multiple intended mechanisms of action, including Fc-mediated cytotoxicity with enhanced ADCC and inhibition of CD70/CD27 signaling, resulting in killing of malignant cells such as leukemia blasts and stem cells.

Definition

cusatuzumab is a defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Upon administration, cusatuzumab selectively binds to, and neutralizes the activity of CD70, which may also induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on a number of solid and hematological tumors. Its overexpression may play an important role in evasion of immune surveillance.
Synonym: anti-CD70 monoclonal antibody ARGX-110
Code name: ARGX-110

Cusatuzumab(1399546-01-0)Related Product Information

• Oleclumab
• ipilimumab
• Dacetuzumab
• Cibisatamab
• Selicrelumab
• Galcanezumab
• Rovalpituzumab
• Tinurilimab
• Zolbetuximab
• Eculizumab